New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Allogene Therapeutics, Inc. (ALLO) vs Vanda Pharmaceuticals Inc. (VNDA)

Allogene Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are of similar size ($235.2M and $231.1M). Vanda Pharmaceuticals Inc. grew revenue faster over the last twelve months: 8.11% against −30.4%. Vanda Pharmaceuticals Inc. has the higher net margin (−119.9% vs −335,973.6%) and the lower return on invested capital (−180.2% vs −119.4%). Across the 16 metrics below, Allogene Therapeutics, Inc. leads on 12 and Vanda Pharmaceuticals Inc. on 4.

Valuation

Metric ALLO VNDA Biotechnology median
P/E n/m n/m 8.49
P/S 45.61 0.91 8.56
P/B 0.55 1.04 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.43 n/m 0.69
EV/Sales (16.66) 0.30 8.00
Earnings yield (101.61%) (134.30%) (35.81%)
Free cash flow yield (50.71%) (72.10%) (25.41%)

Profitability

Metric ALLO VNDA Biotechnology median
Gross margin 100.00% 93.59% 70.18%
Operating margin (342,700.00%) (77.59%) 0.00%
Net margin (335,973.56%) (119.87%) 0.00%
Free cash flow margin (261,473.56%) — 0.00%
Return on equity (49.29%) (82.55%) (51.58%)
Return on assets (36.69%) (55.89%) (45.91%)
Return on invested capital (119.37%) (180.19%) 0.00%

Growth

Metric ALLO VNDA Biotechnology median
Revenue growth (TTM) (30.40%) 8.11% 7.20%
EPS growth (last fiscal year) 34.09% (1,033.33%) 29.04%
Revenue growth, 5-year CAGR — (2.73%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALLO VNDA Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 7.79 1.54 4.79
Net debt to EBITDA 1.24 1.84 1.01

Dividend

Metric ALLO VNDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALLO VNDA Biotechnology median
Market cap 231.06m 235.22m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack